Hero MotoSports Team Rally Successfully Completes Stage 2 at Dakar 2025
Hero MotoSports Team Rally, the motorsport team of the world’s largest manufacturer of motorcycles and scooters - Hero MotoCorp, has successfully completed the second stage at the Dakar Rally 2025 that featured the notoriously challenging 48H Chrono this year at the world’s toughest rally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250106205373/en/
Hero MotoSports Dakar Rally Stage 2 (Photo: Business Wire)
The Botswanan hero Ross Branch delivered an impressive performance, finishing the stage with the 5th fastest time. His teammate, Nacho Cornejo also demonstrated remarkable resilience, securing the 12th place.
With this result, Ross maintains his 3rd position in the overall rankings, a mere 4 seconds behind the second-place holder. Nacho has also been showcasing a strong performance since the start of the race, and now holds an impressive 9th overall position in the rally.
The Hero 450 Rally has been showing remarkable resilience and performance in the Dakar Rally for years now. Completing the 48H Chrono stage yet again without any major issues is a testament to the bike's reliability and the team's outstanding engineering.
Stage 2 was a unique stage, spanning 1006 km over two days. Competitors were required to halt at the nearest of the six designated Break Point zones at 5 pm on Day 1, where they received minimal camping gear and rations to survive the night. By the end of Day 1, both Hero riders had covered 609 km reaching BP E - the second last break point. Starting early today, the competitors continued on the remaining 338 km distance of the special to reach the finish line. To complete the second half of the challenging stage, riders set off on Monday morning in the same order they arrived at their respective rest points.
With tomorrow’s Stage 3, the rally now moves northwards to Al Henakiah, featuring 496 km of timed specials. The stage begins with technical sections, followed by fast stretches that demand high-speed skills. While these fast stages offer opportunities for gains, they also pose significant risks, and a single mistake can prove costly for the competitors.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250106205373/en/
Contacts
For more information:
www.heromotocorp.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.heromotocor
p.com&esheet=54173582&newsitemid=20250106205373&lan=en-US&anchor=www.heromotocor
p.com&index=1&md5=c4cb372feb2682c076fe7c79fd7d6acf | FB: /HeroMotoCorpIndia |
Twitter: @HeroMotoCorp
IG: @HeroMotoCorp
Press Contact:
corporate.communication@heromotocorp.com
Follow the team:
www.heromotosports.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.heromotospo
rts.com&esheet=54173582&newsitemid=20250106205373&lan=en-US&anchor=www.heromotos
ports.com&index=2&md5=3c36805b6e0408140f2b2c48df61a848 | FB: /HeroMotoSports |
IG: @Heromotosports
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Perma-Pipe International Holdings, Inc. Announces $43 Million Contract Award in the Middle East Region10.1.2025 16:23:00 EET | Press release
Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH) today announced it has received a formal letter of award for a development project located in the GCC region. Perma-Pipe will provide thermal insulation, anti-corrosion coatings, and other services from its Abu Dhabi facility. Project commencement is expected to begin in the third quarter of 2025. The value of this project is estimated to exceed $43 million. This project will utilize Perma-Pipe’s anti-corrosion coatings capabilities, fabrication, and the TRACE-THERM® insulation system, a spray-applied polyurethane foam jacketed with a high-density polyethylene casing. Saleh Sagr, Sr. Vice President for Perma-Pipe’s MENA region, commented, “This award follows the successful execution of numerous development projects in the region. Our differentiated coating solutions have proven to be well-suited for technically challenging projects. We would like to thank our customers for this significant award.” David Mansfield, President and CEO
Lenovo Integrates AI and Robotics to Deliver Smarter Retail Solutions10.1.2025 16:00:00 EET | Press release
Lenovo today introduced three new retail solutions that combine the best of robotics and artificial intelligence technologies. Premiering at NRF 2025 in New York City, each solution has been field-tested and proven in commercial settings. Lenovo Retail Content Management Services enables retailers to create, schedule and display digital content across screens store-wide, streamlining multimedia content management and enabling real-time updates and targeted messaging to drive awareness, interest and incremental sales. The complete solution comprises all hardware and software needed, and can be deployed, maintained and managed across multiple locations globally. A leading food and beverage chain has deployed this content management service across 100+ stores and achieved substantial cost savings from dynamically managed promotional campaigns, reduced use of paper marketing materials, and reduced manpower needed to manage both campaigns and devices. Lenovo Retail Robotics with Yunji offer
Institute of Molecular and Clinical Ophthalmology Basel Spinout RhyGaze Closes USD 86 Million Series A Round to Further Novel Gene Therapy for Vision Restoration10.1.2025 15:00:00 EET | Press release
RhyGaze, a biotechnology company based in Basel, Switzerland and Philadelphia, Pa., USA, today announced that it has secured a Series A financing of USD 86 million. The round was led by GV (Google Ventures), alongside Arch Venture Partners, F-Prime Capital and founding investors BioGeneration Ventures and Novartis Venture Fund, who contributed USD 11 million to an earlier seed round. RhyGaze was founded on intellectual property exclusively licensed to the company by the Institute of Molecular and Clinical Ophthalmology Basel (IOB), a scientific institute led by Director Botond Roska, M.D., Ph.D., who is a scientific co-founder of RhyGaze. This funding will enable further development of RhyGaze’s lead clinical candidate, a novel gene therapy for optogenetic vision restoration in diseases causing blindness. Activities to be supported include formal pharmacology and toxicology testing, a non-interventional, observational study to assess potential clinical endpoints in patient groups eligi
Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore10.1.2025 14:30:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). Pove is a recombinant fusion protein therapeutic and dual antagonist of BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) with best-in-class potential being studied for the treatment of Immunoglobulin A nephropathy (IgAN) and other B cell-mediated diseases. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250110168811/en/ Under the terms of the agreement, Vertex will receive an upfront payment, as well as certain regulatory milestone payments and tiered royalties, on net sales of pove in the region of focus for Zai Lab. Zai Lab will utilize its extensive research and deve
Compass Pathways Announces Pricing of Underwritten Offering10.1.2025 14:01:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the pricing of an underwritten offering of 24,014,728 American Depositary Shares (“ADSs”) and in lieu of ADS, to certain institutional investors, pre-funded warrants to purchase up to 11,044,720 ADSs. Each ADS and pre-funded warrant shall be accompanied by a warrant (“ADS Warrant”) to purchase one ADS, which has an exercise price of $5.796 per ADS, representing a 40% premium to the last sale price and will be exercisable following a specified data milestone. The offering price is $4.275 per ADS and accompanying ADS Warrant, and $4.2649 per pre-funded warrant and accompanying ADS Warrant. All of the securities are to be sold by Compass. The offering is expected to close on or about January 13, 2025, subject to satisfaction of customary closing conditions. The offering was led by Deep Track Capital and included participation
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom